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 Background: To investigate stromal variables including angiogenesis, lymphangiogenesis, and matrix metalloproteinase 
(MMP) in the serum of patients with urothelial carcinoma of the bladder (UCB) and to evaluate their associa-
tion with histopathological characteristics and clinical outcome.
 Material/Methods: Protein levels of vascular endothelial growth factors-A, -C, -D (VEGF-A/-C/-D), their receptors- VEGF-R2 and -R3 
(VEGF-R2/-R3), and matrix metalloproteinases 2, -3, and -7 (MMP-2, MMP-3, MMP-7) were quantified in the 
blood serum samples of 71 patients with UCB before radical cystectomy (RC). Samples of patients with non-
invasive UCB or no history of UCB were investigated as controls (n=20). Protein levels in the serum were mea-
sured using a flow cytometric cytokine assay.
 Results: A positive association for VEGF-D (p<0.001) and an inverse association for MMP-2 (p=0.017) were observed in 
patients with positive lymph node (LN) status at the time of RC. VEGF-A (p<0.001), VEGF-C (p<0.001), MMP-2 
(p<0.001), and MMP-7 (p=0.005) serum levels were different in serum of patients with invasive UCB com-
pared with non-invasive UCB or healthy individuals. None of the serum markers were associated with disease 
progression.
 Conclusions: High VEGF-D and low MMP-2 serum levels predict LN metastasis in patients with UCB at the time of RC. VEGF-A, 
VEGF-C, MMP-2, and MMP-7 serum levels varied significantly between invasive and non-invasive disease as 
well as in comparison with healthy individuals. Clinical implementation of these marker serum measurements 
may be valuable to select high-risk patients with more invasive or nodal-positive disease.
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Growth Factor D
 Abbreviations: CSS – cancer-specific survival; ECM – extracellular matrix; LN – lymph node; LVI – lymphovascular inva-
sion; ml – milliliters; MMP – matrix metalloproteinases; OS – overall survival; RC – radical cystectomy; 
rpm – revolutions per minute; ROC – receiver-operating characteristic; TIMP-2 – tissue inhibitor metallo-
proteinase-2; TURB – transurethral resection of the bladder; UCB – urothelial carcinoma of the bladder; 
VEGF – vascular endothelial growth factor; VEGF-R – vascular endothelial growth factor receptor
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Background
Urothelial carcinoma of the urinary bladder (UCB) is one of the 
most frequent types of cancer worldwide, with an estimat-
ed 74 690 new cases and 15 580 deaths in the United States 
in 2014 [1]. Of all newly diagnosed cases of UCB, about 70% 
present as superficial tumors (stages Ta, T1, or tumors in situ 
[Tis]), but as many as 50–70% of those superficial tumors will 
recur and roughly 10–20% will progress to muscle-invasive dis-
ease (T2–4) [2]. Radical cystectomy (RC) with extended pelvic 
lymph node (LN) dissection is the standard treatment for local-
ized muscle-invasive bladder cancer [3] and provides local con-
trol and long-term cancer-specific survival of the patients [4].
Angiogenesis and lymphangiogenesis play a critical role in tu-
mor growth and systemic dissemination of cancer cells and 
seem to be of prognostic relevance in UCB [5–7]. Nevertheless, 
the mechanisms of angiogenesis and lymphangiogenesis are 
complex. Vascular endothelial growth factors (VEGFs) and their 
receptors (VEGF-R) are some of the key angiogenic factors 
that stimulate the formation of new blood vessels and tumor 
growth [7,8]. In recent years, several studies have shown that 
VEGFs and VEGF-Rs have an influence on metastatic spread and 
disease recurrence in various carcinomas including UCB [9–13].
Matrix metalloproteinases (MMPs) are a family of structurally 
related zinc-dependent endopeptidases collectively capable of 
degrading essentially all components of the extracellular ma-
trix (ECM) [14]. MMPs have important functions in patholog-
ic conditions characterized by excessive degradation of ECM, 
such as tumor invasion and metastasis [15,16]. In the present 
study, we focused on those MMPs having the most impact on 
bladder carcinogenesis, such as: the gelatinases MMP-2 [17,18], 
the stromelysin MMP-3 [16] and the matrilysin MMP-7 [14,16].
MMPs and VEGFs are important players in tumor angiogenesis 
and tumor growth [19] and there is some evidence that MMPs 
may interact with proteins of the VEGF-family [20,21]. Both, 
MMPs and the VEGF-family may therefore serve as potential 
prognostic and/or therapeutic targets in like bladder cancer.
The relevance of all the mentioned stromal variables as prog-
nostic parameters for UCB is unclear and none of them are im-
plemented in daily routine practice. Furthermore, not all have 
been investigated and contemporaneously tested in serum of 
patients with UCB.
This study was designed to evaluate the expression of various 
stromal variables involved in angio- and lymphangiogenesis 
in serum samples of patients with UCB undergoing RC and to 
compare them with clinical and histopathological character-
istics as well as with clinical outcome.
Material and Methods
Patients
A total number of 91 individuals divided in three different 
groups were included in this study: The main cohort consist-
ed of 71 serum samples from patients with aggressive UCB 
who underwent RC with bilateral pelvic LN dissection at the 
University Hospital Zurich between 2009 and 2013. Additional 
blood serum samples of patients were investigated as con-
trols: One group consisted of 10 patients with histological-
ly confirmed non-invasive UCB (pTa) during transurethral re-
section of the bladder (TURB). The other group comprised 10 
patients with normal white light cystoscopy and no history of 
UCB. Serum samples were all taken preoperatively or before 
white light cystoscopy.
All pathological specimens were processed according to stan-
dardized institutional protocols. TURB and RC specimens were 
staged according to the TNM classification [3]. For this study, 
only post-RC patients were followed on a regular basis. Every 
6 to 12 months a CT scan was performed to exclude meta-
static disease. The median follow-up period for the RC co-
hort (n=71) was 17.2 months (range 0.4 to 48.5 months). The 
study was approved by the local scientific ethics committee 
Kantonale Ethikkommission Zürich (http://www.kek.zh.ch/, ap-
proval no.: StV-Nr. 02/2009 & 0352/2012). Each patient signed 
an informed consent.
Serum level measurements
Serum samples were obtained preoperatively or before white 
light cystoscopy. Venous blood (10 ml) was collected and cen-
trifuged at 900 rpm for 10 minutes. The serum was then sep-
arated, aliquoted in 2 ml fractions and stored at -80°C until 
further use. Protein serum levels were assessed by the multi-
plexed particle-based flow cytometric cytokine assay (Vignali, 
2000). Kits for VEGF-A, VEGF-C and VEGF-D were purchased 
from Millipore (Zug, Switzerland), for MMP-2, MMP-3 and 
MMP-7 from R&D Systems (Oxon, UK) and for VEGF-R2 and 
VEGF-R3 from eBioscience (Vienna, Austria). The procedures 
closely followed the manufacturer’s instructions. The analysis 
was conducted using a conventional flow cytometer (Guava 
EasyCyte Plus, Millipore, Zug, Switzerland) [22].
Statistical analysis
All statistical analyses were performed using SPSS Statistics 
version 22 (SPSS, IBM Corp., Armonk, NY). Associations be-
tween measured parameters were assessed using the chi-
square test for categorical variables and the Mann-Whitney U 
test for continuous variables. In order to find the optimal cut-
off point for continuous variables with significant differences 
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between clinicopathological features, receiver-operating char-
acteristic (ROC) curves were created for different outcome 
measures at interest. The optimal value for each outcome pa-
rameter was identified by minimising the distance from the 
ROC curve to the top left corner of the ROC plot [23]. To ana-
lyze different groups of patients regarding the serum expres-
sion of investigated markers, the ANOVA test was used. Time 
to cancer-specific survival (CSS) was calculated from the date 
of RC to the date of death (death only from primary cancer). 
Time to overall survival (OS) was calculated from the date of 
RC to the date of death (death from all causes). Differences 
between survival estimates were evaluated by the log-rank 
test or by Cox regression analyses. Differences were consid-
ered significant at p<0.05.
Results
Clinicopathologic charateristics and their association with 
prognosis
All clinicopathologic characteristics of the RC cohort are sum-
marized in Table 1. The median age of patients at the time of 
diagnosis was 72.4 years (range 45–87) and 55 (78%) were 
male. Among the 71 patients analyzed, organ-confined tumor 
stages (pTis to £pT2) were present in 34 (48%) and extraves-
ical disease (pT3 and pT4) in 37 (52%).
Univariate analysis of clinicopathologic features for CSS and OS 
is provided in Table 2. Altogether, 28 deaths were documented 
(39.4%). CSS occured in 20 cases (28.2%). The presence of LVI, 
LN metastasis, venous invasion, and higher tumor stage were 
all associated with shorter CSS and OS in univariate analysis. 
LVI and positive LN staging (p<0.001 and p=0.001, respective-
ly) were the best predictors for CCS and OS.
Expression of stromal variables in blood serum and 
its association with clinicopathologic parameters and 
prognosis
Protein levels of VEGFs, VEGF-Rs, and MMPs detected in in 
serum were compared with clinicopathologic characteristics 
(age, sex, tumor stage, adjacent carcinoma in situ, LVI, ve-
nous invasion, LN staging) by using the Mann-Whitney U Test. 
VEGF-D serum levels were positively associated with positive 
LN stage (p=0.002) and LVI (p=0.019), whereas MMP-2 serum 
levels showed an inversive association with positive LN stage 
(p=0.062). None of the other markers were associated with 
any of the tested clinicopathologic characteristics (data not 
shown). After defining optimal cut-off points for VEGF-D and 
MMP-2 regarding the outcome LN metastasis, the parameters 
were again compared with LN metastasis and with survival. 
The results are depicted in Table 3. In keeping with previous 
Variable Categorization n analyzable * %
Total (n=71)*
Clinicopathologic data: 
Month of follow-up (mean, range) 18.83 (0.4–48.5)
Age at diagnosis (median, range) 72.4 (45–87) years
 <70 years 33 47
 ³70 years 38 53
Sex
 Female 16 22
 Male 55 78
Tumor stage (WHO 1973**)
 pTis 3 4
 pTa 2 3
 pT1 13 18
 pT2 16 23
 pT3 20 28
 pT4 17 24
Histologic grade (WHO 2004***)
 Low grade 0 0
 High grade 71 100
Adjacent carcinoma in situ
 No 61 86
 Yes 10 14
Lymphovascular invasion
 No 48 68
 Yes 23 32
Venous Invasion
 No 57 80
 Yes 14 20
Lymph node positive 
 No 49 69
 Yes 22 31
Investigated serum markers
VEGF-A (pg/mL) (median, range) 260 (40–892)
VEGF-C (pg/mL) (median, range) 126 (61–313)
VEGF-D (pg/mL) (median, range) 368 (25–2284)
VEGF-R2 (ng/mL) (median, range) 17.2 (5.7–33.2)
VEGF-R3 (ng/mL) (median, range) 98.6 (35.2–199.1)
MMP-2 (ng/mL) (median, range) 117 (54–535)
MMP-3 (ng/mL) (median, range) 12.3 (4.9–38.6)
MMP-7 (pg/mL) (median, range) 1993 (828–19057)
Table 1.  RC cohort patient and tumor characteristics and results 
of investigated stromal variables.
* All patients who underwent RC; ** Staging and grading 
according to the 1973 WHO classification system; *** Staging 
and grading according to the 2004 WHO classification system.
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Variable Categorization
VEGF-D MMP-2
<300 pg/mL ³300 pg/mL p <100 ng/mL ³100 ng/mL p
Lymph node positive*
 No 23 26
<0.001
12 37
0.017
 Yes 1 21 12 10
Cancer-specific death (20 events)**
 No 6 14
0.463
7 13
0.488
 Yes 18 33 17 34
Overall death (28 events)**
 No 11 17
0.772
10 18
0.493
 Yes 13 30 14 29
Table 3. Comparison of VEGF-D and MMP-2 (dichotomized) with lymph node stage and survival (n=71).
* Fisher‘s exact Test (2-sided); bold face representing p-values <0.05; ** Log Rank test (2-sided); bold face representing p-values <0.05.
Variable Categorization
Cancer specific survival (CSS) Overall survival (OS)
n Events p* n Events p*
Age at diagnosis
 <70 years 33 10
0.397
33 12
0.818
 ³70 years 38 10 38 16
Sex
 Female 16 6
0.228
16 8
0.218
 Male 55 14 55 20
Tumor stage (WHO 1973**)
 <pT3 34 5
0.001
34 9
0.003
 ³pT3 37 15 37 19
Adjacent carcinoma in situ
 No 61 18
0.289
61 26
0.09
 Yes 10 2 10 2
Lymphovascular invasion
 No 48 7
<0.001
48 14
<0.001
 Yes 23 13 23 14
Venous Invasion
 No 57 14
0.026
57 20
0.019
 Yes 14 6 14 8
Lymph node positive
 No 49 6
<0.001
49 14
0.001
 Yes 22 14 22 14
Table 2. Univariate analysis of clinicopathological features for cancer specific survival and overall survival (n=71).
* Log Rank test (2-sided); bold face representing p-values <0.05; ** Staging and grading according to the 1973 WHO classification 
system.
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findings, VEGF-D serum levels (cutoff ³300 pg/mL) correlat-
ed positively with LN stage (p<0.001) and with LVI (p=0.015). 
Furthermore, low MMP-2 serum levels (cutoff ³100 ng/mL) 
were associated with LN metastasis (p=0.017). Using these 
cut-off points, VEGF-D showed a high sensitivity (0.95) and 
low specificity (0.47), while MMP-2 showed good specificity 
and low sensitivity (sensitivity=0.55, specificity=0.76) for the 
detection of LN metastasis. To determine if a correlation be-
tween high VEGF-D and low MMP-2 serum levels exists, linear 
regression was performed. Linear regression showed no asso-
ciation between serum levels of VEGF-D and MMP-2 by giving 
a low coefficient of determination (R2=0.027).
No associations were found between these 2 tested serum 
markers and CSS and overall deaths, respectively (Table 3). 
Additionally, further cut-off points for VEGF-D (³500, ³1000 
and ³1500 pg/mL) and MMP-2 (³200, ³300, and ³400 ng/mL) 
have been evaluated for its association with disease course. 
None of the cut-off points for these 2 markers showed any 
association with CSS (data not shown). VEGF-D and MMP-2, 
as well as all other tested serum markers, showed no associ-
ation with CSS when tested as continuous variables in Cox re-
gression analysis (Supplemental Table 1).
Serum levels of stromal variables considering grade of 
invasiveness
For the analysis of serum levels in patients with invasive UCB 
in comparison with non-invasive UCB or healthy individuals, 
additional blood serum samples of patients with non-invasive 
UCB or no history of UCB were investigated. Figure 1 shows 
boxplots of all investigated stromal markers.
VEGF-A (p<0.001), VEGF-C (p<0.001) and MMP-7 (p=0.005) were 
elevated in serum of patients with invasive UCB compared to 
patients with non-invasive UCB or healthy individuals. In con-
trast, lower MMP-2 (p<0.001) serum levels were found in the 
invasive UCB group compared to the non-invasive UCB group 
or negative controls. No significant differences between the 
expression in UCB patients, non-invasive UCB patients, and 
healthy individuals were found for VEGF-D (p=0.588), VEGF-R2 
(p=0.168), VEGF-R3 (p=0.074), or MMP-3 (p=0.509).
Discussion
Lymphatic metastasis is a common early event in aggressive 
UCB, and the presence of LN metastasis is associated with 
Variable
Univariate analysis
HR 95% CI p value
Clinico-pathological parameters
Age (<70 vs. ³70 years) 0.674 0.269 1.688 0.400
Tumor Stage (WHO1973) (<T3 vs. ³T3) 5.188 1.706 15.778 0.004
Adjacent carcinoma in situ 0.462 0.107 1.997 0.301
Lymphovascular invasion 8.979 3.116 25.874 <0.001
Venous Invasion 2.875 1.084 7.626 0.034
Lymph node positive 10.188 3.332 31.15 <0.001
Serum markers
 VEGF-A (pg/mL) 1.001 0.998 1.003 0.708
 VEGF-C (pg/mL) 0.998 0.990 1.006 0.619
 VEGF-D (pg/mL) 1.000 0.999 1.001 0.383
 VEGF-R2 (ng/mL) 0.967 0.894 1.046 0.404
 VEGF-R3 (ng/mL) 1.000 0.988 1.012 0.989
 MMP-2 (ng/mL) 1.000 1.000 1.000 0.737
 MMP-3 (ng/mL) 1.000 1.000 1.000 0.478
 MMP-7 (pg/mL) 1.000 1.000 1.000 0.711
Supplemental  Table 1. Univariate cox regression analyses of clinicopathological parameters and tested serum markers for cancer-
specific survival.
Univariate cox regression analyses of clinicopatholgical parameters and tested serum markers for CSS. Significant associations were 
found between CSS and higher tumor stage (p=0.004), LVI (p<0.001), venous invasion (p=0.034) and positive LN stage (p<0.001). None 
of the tested serum markers showed any association with CSS in univariate cox regression analysis.
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poor outcome following radical surgery. The presence of LVI 
and lymphangiogenesis can be considered as morphologic pre-
cursors for the ocurrence of micrometastasis in clinically lo-
calized forms of UCB [12,24]. A range of experimental stud-
ies have suggested that various stromal variables involved in 
lymphangio- and angiogenesis may serve as biomarkers for the 
diagnosis and prognosis of patients with UCB [25]. However, 
few studies have been conducted to investigate the clinical 
and prognostic value of these markers in patients’ sera. Our 
study is the first comprehensive analysis of the VEGF family 
and MMPs in the serum of patients with bladder cancer. We 
found that high VEGF-D levels and low MMP-2 serum levels 
were more common in LN-positive disease. Furthermore, 4 
investigated markers (VEGF-A, VEGF-C, MMP-2, and MMP-7) 
were changed in invasive UCB compared to non-invasive UCB 
or negative controls and might therefore be potential candi-
dates for the prediction of invasive bladder cancer.
The expression of VEGF-D plays a major role during the meta-
static process in various cancers, including UCB [8,9]. A recent 
study by von Hardenberg et al. [12] on the expression and pre-
dictive value of lymph-specific markers in UCB specimens of 
119 patients showed that VEGF-D overexpression was signif-
icantly associated with LVI, LN involvement, and reduced CSS. 
Another study, by Herrmann et al. [26], investigated the role 
of VEGF-D in RC specimens of patients with UCB. VEGF-D over-
expression correlated with higher stage, LN metastasis, and 
reduced CSS. Unlike these publications, Miyata et al. [6] re-
ported that VEGF-D was not associated with disease outcome. 
Similar to these tissue-based results, we observed a correlation 
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Figure 1.  Markers were measured in serum of patients with invasive UCB (n=66) and in patients with pTa UCB or no history of UCB 
(n=22). For VEGF-A, only 85 samples could be evaluated. Dots represent patient samples. Horizontal lines represent mean 
values. *** p<0.001; ** p<001; * p<0.05. VEGF-A (A) and VEGF-C (B) were elevated in serum of patients with invasive UCB 
compared to patients with non-invasive (pTa) UCB or no history of UCB. VEGF-D (C), VEGF-R2 (D), VEGF-R3 (E) were equal in 
serum of patients with invasive UCB compared to patients with non-invasive (pTa) UCB or no history of UCB. MMP-2 (F) was 
lower in serum of patients with invasive UCB compared to patients with non-invasive (pTa) UCB or no history of UCB. MMP-3 
(G) was equal in serum of patients with invasive UCB compared to patients with non-invasive (pTa) UCB or no history of 
UCB, whereas MMP-7 (H) was elevated in serum of patients with invasive UCB compared to patients with non-invasive (pTa) 
UCB or no history of UCB.
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of VEGF-D serum levels with LVI and LN metastasis. However, 
because VEGF-D did not show any association with more in-
vasive disease or disease outcome, it might be not an ideal 
serum biomarker for UCB. In our study, VEGF-D serum levels 
were associated with low specificity but had high sensitivity 
for the prediction of LN metastasis. Preoperative low VEGF-D 
serum levels might therefore put patients at very low risk of 
having LN-positive disease. However, more studies with more 
patients are needed to confirm this hypothesis.
Matrix metalloproteinases are the most important proteolytic 
enzymes catalyzing the degradation of ECM, which is essen-
tial for tumor invasion and metastasis [16]. An important rep-
resentative of MMPs, MMP-2, physiologically degrades typ IV 
collagen, the major component of the basement membrane. 
Conflicting results have been reported regarding the prognos-
tic value of MMP-2 in bladder cancer. Earlier studies by Vasala 
et al. [17] and by Kanamaya et al. [27] claimed high mRNA and 
protein levels to be significant risk factors for poor disease-
specific survival, while Hara et al. [28] and Grignon et al. [29] 
found no correlation between MMP-2 levels and prognosis. 
MMP-2 levels in serum were observed to be similar in blad-
der cancer patients and healthy controls, but higher in pa-
tients at increased risk for disease recurrence and cancer-as-
sociated death [30]. Others found MMP-2 plasma levels to 
be elevated in patients with UCB compared to healthy con-
trols, but without prognostic relevance [18]. Vasala et al. [31] 
showed that MMP-2 serum expression in tumor tissue was 
decreased in comparison with controls, but no correlation 
was found with pathological parameters. Considering our co-
hort, we observed that decreased serum levels of MMP-2 cor-
related inversely with more invasive and LN-positive disease. 
These controversial results may be explained by the fact that 
MMP-2 is also present in the serum as a proactive zymogen 
and in complexed form with tissue inhibitor metalloprotein-
ase-2 (TIMP-2). Serum levels of these inactive MMP-2 vari-
ants were shown to be independent favorable prognostic fac-
tors in bladder cancer, indicating that endogenous inhibition 
of MMP-2 activity has not only biological but also prognostic 
relevance [17,31]. Furthermore, another study by Vasala et al. 
showed that a decrease in circulation MMP-2: TIMP-2 com-
plex levels was associated with unfavorable survival in bladder 
cancer patients [32]. Our results seem to be in line with these 
findings, as the assay we used in our study can also measure 
the proactive form of MMP-2. Another reason for our findings 
may be based on the fact that we assessed MMP-2 serum lev-
els by a multiplexed particle-based flow cytometric cytokine 
assay and not an ELISA assay. To the best of our knowledge, 
the only work that investigated MMP-2 serum levels in UCB 
by multiplexed particle-based flow cytometric cytokine assay 
found that MMP-2 serum levels were decreased in less inva-
sive UCB, which is in line with our investigation [33]. Further 
studies, testing different methods and antibody kits for the 
measurement of MMP-2 in the serum of bladder cancer pa-
tients are needed to address this issue.
For MMP-7, we found elevated serum levels in more invasive 
UCB but no assocation with disease course. However, others 
have assessed MMP-7 serum levels in UCB and found that el-
evated MMP-7 serum levels were associated with lymph node 
metastasis [14] and shorter CSS [14,33,34].
Here, we propose that LN-positive UCB is characterized by 
high VEG-D serum levels and low MMP-2 serum levels. Both 
VEGF-D and MMP-2 are considered to be involved in angio-
genesis. There is some evidence that MMPs interact with the 
VEGF-family through different signaling pathways [21,35,36]. 
Recently, it was postulated that VEGF may regulate MMP-2 
in glioblastoma [21]. However, there are no reports of a di-
rect connection or interaction between VEGF-D and MMP-2.
VEGF-A and VEGF-C are other key players in the processes of 
angiogenesis and lymphangiogenesis [8,9]. Miyata et al. [6] re-
ported that expression of VEGF-A and VEGF-C in tissue sam-
ples of 126 patients with nonmetastatic bladder cancer cor-
related positively with tumor stage and grading. In line with 
these findings, we found that both VEGF-A and VEGF-C serum 
expression levels had a significant association with tumor in-
vasiveness. However, no correlation was found between se-
rum marker levels and nodal-positive disease.
For VEGF-R2 and VEGF-R3 serum levels we found no associa-
tions with clinico-pathological features or prognosis in blad-
der cancer. There is no literature available regarding VEGF-Rs 
in serum of UCB. However, one study has reported that high-
er VEGF-R3 expression in tumours is associated with reduced 
CSS in UCB [12].
An enhanced identification of patients who are at high risk 
of disease progression or cancer-specific death despite radi-
cal surgery remains an important challenge in the treatment 
of UCB. Taken together, the results of our study suggest that 
some of the investigated stromal variables indicate LN-positive 
disease and/or a higher stage of tumor invasiveness. As a con-
sequence, clinical implementation of serum assays might be 
valuable to better select patients at high risk for more inva-
sive disease than assessed preoperatively by TURB. Moreover, 
stromal variable serum measurements might have potential for 
identifying patients with presumable LN metastasis who may 
benefit from more aggressive treatment strategies. However, 
further studies need to be conducted to confirm this hypoth-
esis and to assess the prognostic value of these tested mark-
ers in larger cohorts.
Our study has some limitations, including its rather small num-
ber of patients and the relatively short follow-up period, which 
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limits the ability to draw firm conclusions. However, our co-
hort is representative, as all well known pathological indica-
tors for poor prognosis worked well to predict CSS or OS. The 
lack of tissue analysis in our study for these proteins has to 
be considered as another limitation.
Further studies with more patients are needed to clarify the 
role of VEGF-D and MMP-2 in bladder cancer. It would be of 
interest to perform different methods for protein serum mea-
surements and to look at the expression levels in tumor tissue.
Conclusions
We showed that higher VEGF-D serum levels are more com-
mon in patients with LVI or LN metastasis at the time of RC. 
Furthermore, low serum levels of MMP-2 defined invasive UCB 
and were more frequent in patients with node-positive disease. 
In addition, VEGF-A, VEGF-C and MMP-7 serum levels varied sig-
nificantly between invasive and non-invasive disease, as well 
as in comparison with healthy individuals. However, none of 
the investigated markers were of prognostic value. Our find-
ings suggest that implementation of these serum measure-
ments might be useful to select high-risk patients with more 
invasive or nodal-positive disease.
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